TY - JOUR
T1 - Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
AU - Amsterdam UMC COVID-19 S3/HCW study group
AU - Caniels, Tom G.
AU - Bontjer, Ilja
AU - van der Straten, Karlijn
AU - Poniman, Meliawati
AU - Burger, Judith A.
AU - Appelman, Brent
AU - Lavell, H. A.Ayesha
AU - Oomen, Melissa
AU - Godeke, Gert Jan
AU - Valle, Coralie
AU - Mögling, Ramona
AU - van Willigen, Hugo D.G.
AU - Wynberg, Elke
AU - Schinkel, Michiel
AU - van Vught, Lonneke A.
AU - Guerra, Denise
AU - Snitselaar, Jonne L.
AU - Chaturbhuj, Devidas N.
AU - Martin, Isabel Cuella
AU - Moore, John P.
AU - de Jong, Menno D.
AU - Reusken, Chantal
AU - Sikkens, Jonne J.
AU - Bomers, Marije K.
AU - de Bree, Godelieve J.
AU - van Gils, Marit J.
AU - Eggink, Dirk
AU - Sanders, Rogier W.
N1 - Funding Information: We thank P. Bieniasz for donating cells and reagents for pseudovirus neutralization assays; J. Reimerink, F. Brouwer, M. Hoogerwerf, and T. Munawar for technical assistance; B. J. Verkaik, O. J. A. Figaroa, P. J. de Vries, T. M. Boertien, and M. Prins for support of the COSCA study; and all the participants of the COSCA and S3/HCW studies. This work was supported by the Netherlands Organization for Scientific Research (NWO) Vici grant (to R.W.S.); Bill & Melinda Gates Foundation, Collaboration for AIDS Vaccine Discovery (CAVD) grant INV-002022 (to R.W.S.); Amsterdam UMC AMC Fellowship (to M.J.v.G.); Bill & Melinda Gates Foundation, COVID-19 Wave 2 mAbs grant INV-024617 (to M.J.v.G.); Fondation Dormeur, Vaduz (to M.J.v.G. and R.W.S.); HIVRAD grants P01 AI 110657 (to J.P.M.) R01 AI 36082 (to J.P.M.); Netherlands Organization for Health Research and Development ZonMw; and the Amsterdam UMC Corona Research Fund (Amsterdam UMC COVID-19 S3/HCW study group). Publisher Copyright: © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Emerging SARS-CoV-2 variants of concern (VOCs) pose a threat to human immunity induced by natural infection and vaccination. We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50). Spike binding and neutralization against all three VOCs were substantially reduced in most individuals, with the largest four- to sevenfold reduction in neutralization being observed against B.1.351. While hospitalized patients with COVID-19 and vaccinees maintained sufficient neutralizing titers against all three VOCs, 39% of nonhospitalized patients exhibited no detectable neutralization against B.1.351. Moreover, monoclonal neutralizing antibodies show sharp reductions in their binding kinetics and neutralizing potential to B.1.351 and P.1 but not to B.1.1.7. These data have implications for the degree to which pre-existing immunity can protect against subsequent infection with VOCs and informs policy makers of susceptibility to globally circulating SARS-CoV-2 VOCs.
AB - Emerging SARS-CoV-2 variants of concern (VOCs) pose a threat to human immunity induced by natural infection and vaccination. We assessed the recognition of three VOCs (B.1.1.7, B.1.351, and P.1) in cohorts of COVID-19 convalescent patients (n = 69) and Pfizer-BioNTech vaccine recipients (n = 50). Spike binding and neutralization against all three VOCs were substantially reduced in most individuals, with the largest four- to sevenfold reduction in neutralization being observed against B.1.351. While hospitalized patients with COVID-19 and vaccinees maintained sufficient neutralizing titers against all three VOCs, 39% of nonhospitalized patients exhibited no detectable neutralization against B.1.351. Moreover, monoclonal neutralizing antibodies show sharp reductions in their binding kinetics and neutralizing potential to B.1.351 and P.1 but not to B.1.1.7. These data have implications for the degree to which pre-existing immunity can protect against subsequent infection with VOCs and informs policy makers of susceptibility to globally circulating SARS-CoV-2 VOCs.
UR - http://www.scopus.com/inward/record.url?scp=85114320268&partnerID=8YFLogxK
U2 - https://doi.org/10.1126/sciadv.abj5365
DO - https://doi.org/10.1126/sciadv.abj5365
M3 - Article
C2 - 34516917
SN - 2375-2548
VL - 7
SP - eabj5365
JO - Science advances
JF - Science advances
IS - 36
M1 - eabj5365
ER -